BrightPath Biotherapeutics Co., Ltd.
BrightPath Biotherapeutics Co., Ltd. (JPX: 4594) is trading at ¥49.00, about ₹30 at today's JPY/INR rate, as of 29 Sep 2026, 2:30 AM ET. Indian residents can buy BrightPath Biotherapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
¥48.00
Today's high
¥50.00
52 week low
¥43.00
52 week high
¥96.00
4594 opened at ¥49.00, closed previously at ¥49.00, and has traded between ¥43.00 and ¥96.00 over the past 52 weeks.
About
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Key statistics
Avg. volume
1.45M
Market cap
¥4.12B
P/E Ratio
-3.83
Price-to-sales ratio
66387.10
Enterprise value
¥2.54B
Free cash flow yield
0.00%
Debt-to-equity ratio
0.00
Return on equity
-93.35%
ROIC
-84.14%
Beta
1.30
Dividend yield
0.00%
Last dividend
¥0.00
Financial overview
Revenue
¥84.00K
Earnings per share
-¥11.70
Free cash flow
-¥1.37B
Net profit margin
-2570440.32%
Gross margin
62.90%
EBITDA
-¥1.30B
Revenue growth
-92.59%
Similar securities
This is not an investment recommendation
How to buy BrightPath Biotherapeutics from India
Indian residents can buy BrightPath Biotherapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to JPY.
Search for BrightPath Biotherapeutics and place an order
Find BrightPath Biotherapeutics by name or by its ticker, 4594, and choose an order type. The Tokyo Stock Exchange typically trades in units of 100 shares. BrightPath Biotherapeutics trades 5:30 am – 12:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your BrightPath Biotherapeutics position in JPY and INR. BrightPath Biotherapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in BrightPath Biotherapeutics from India
Trading and taxes when buying BrightPath Biotherapeutics from India
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm JST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneBrightPath Biotherapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- Estate or inheritance tax
- May applyJapan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir.Estate tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy BrightPath Biotherapeutics stock?
Yes. BrightPath Biotherapeutics (4594) has been listed on the Tokyo Stock Exchange since 2015, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to JPY. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one BrightPath Biotherapeutics share cost in rupees?
One BrightPath Biotherapeutics share is ¥49.00 — about ₹30 at a JPY/INR rate of 0.6107 on 28 Sep 2026. Both the BrightPath Biotherapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying BrightPath Biotherapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of BrightPath Biotherapeutics?
The Tokyo Stock Exchange typically trades in units of 100 shares.
How are gains on BrightPath Biotherapeutics shares taxed in India?
Japan generally does not levy capital gains tax on non-resident individual investors, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the JPY/INR rate on the purchase and the sale date, so the rupee move counts alongside the BrightPath Biotherapeutics price. Paasa issues a capital-gains statement for your return.
Does BrightPath Biotherapeutics pay a dividend?
No. BrightPath Biotherapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade BrightPath Biotherapeutics from India?
The Tokyo Stock Exchange trades 5:30 am – 12:00 pm IST in Indian time. It also halts for lunch, 8:00 am – 9:00 am IST. Orders can only execute during that window.
Is there estate or inheritance tax on BrightPath Biotherapeutics shares held from India?
Japan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir. It applies to your overall holdings in that jurisdiction rather than to any one position.
Do I have to declare BrightPath Biotherapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your BrightPath Biotherapeutics holding, its cost and its closing value.
How do I sell BrightPath Biotherapeutics and bring the money back to India?
You sell during market hours (5:30 am – 12:00 pm IST) and the proceeds settle in JPY in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.